***Background.*** The importance of antifungal surveillance was highlighted by the increasing resistance among certain species and breakthrough infections. We evaluated 1,846 fungal clinical isolates against 9 antifungals using CLSI reference broth microdilution methods (BMD). Additionally, 1,206 isolates were tested using polysorbate-80 (P-80).

***Methods.*** 1,846 isolates collected in 2013 (31 countries) were tested by CLSI BMD and interpretive criteria. Echinocandins (EC), amphotericin B (AMB) and fluconazole (FLC) were also tested using 0.002% P-80 supplemented broth. Isolates were identified using MALDI-TOF MS and/or DNA sequencing.

***Results.*** EC, AMB and FLC were active against common *Candida* spp. (Table). EC-resistance ranged from 0.0 to 2.8% (anidulafungin for *C. glabrata* \[CGLA\]). 11.9 and 11.6% of the CGLA and *C. tropicalis* were resistant to FLC, respectively. Two *A. fumigatus* displayed elevated MIC values for itraconazole (≥4 µg/mL). All *C. neoformans*had MIC \< epidemiological cutoff values for azoles. P-80 lowered the MIC values for EC for all species, but not for FLC. AMB MIC values were lower and ranges broader (0.03-0.5 µg/mL) when compared with reference BMD (0.5-2 µg/mL).

  Organism (no. tested \[no. tested with P-80\])   MIC/MEC~50/90~ for CLSI BMD (with P-80)                                                 
  ------------------------------------------------ ----------------------------------------- --------------------------- ----------------- -----------------------
  *C. albicans* (712 \[475\])                      0.015/0.06 (≤0.008/≤0.008)                0.03/0.03 (≤0.008/≤0.008)   1/1 (0.06/0.12)   0.12/0.25 (0.25/0.25)
  *C. glabrata* (252 \[156\])                      0.06/0.12 (0.015/0.015)                   0.03/0.06 (≤0.008/≤0.008)   1/1 (0.12/0.12)   8/64 (4/32)
  *C. parapsilosis* (215 \[149\])                  2/2 (1/2)                                 0.25/0.5 (0.06/0.06)        1/1 (0.12/0.25)   1/2 (1/4)
  *C. tropicalis* (155 \[90\])                     0.015/0.03 (≤0.008/≤0.008)                0.03/0.03 (≤0.008/≤0.008)   1/1 (0.06/0.12)   0.5/32 (0.5/1)
  *C. krusei* (49 \[29\])                          0.06/0.06 (0.03/0.03)                     0.12/0.25 (0.03/0.03)       1/2 (0.25/0.25)   32/64 (32/64)
  *A. fumigatus* (142 \[94\])                      ≤0.008/0.03 (≤0.008/≤0.008)               0.03/0.03 (≤0.008/≤0.008)   2/2 (0.25/0.5)    -/-

***Conclusion.*** EC and azoles were potent against yeasts and moulds. P-80 use broadened MIC ranges for AMB; however, differences in the growth patterns in RPMI + P-80, requirement for new QC ranges and a possible effect in cell growth reported previously in bacteria might be an impediment to the use of P-80 for antifungal BMD testing.
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